Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paliperidone ER open-label extension in geriatric schizophrenia
NCT00752427Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Jun 2004
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of paliperidone in schizophrenia, sponsored by Johnson & Johnson. Primary endpoint: Long-term assessment of safety and tolerability at 24 weeks. Started Jun 2004; status: completed.
02
Drugs
paliperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00752427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00752427.